Skip to main content

Recombinant Human Claudin 18.2 (Active) protein is a Human Full Length protein, in the 1 to 261 aa range, expressed in HEK 293, with >95% purity and < 1 EU/µg endotoxin level.

Be the first to review this product! Submit a review

Key facts

Purity
>95% HPLC
Endotoxin level
< 1 EU/µg
Expression system
HEK 293 cells
Tags
Tag free
Biologically active
Yes

Amino acid sequence

M A V T A C Q G L G F V V S L I G I A G I I A A T C M D Q W S T Q D L Y N N P V T A V F N Y Q G L W R S C V R E S S G F T E C R G Y F T L L G L P A M L Q A V R A L M I V G I V L G A I G L L V S I F A L K C I R I G S M E D S A K A N M T L T S G I M F I V S G L C A I A G V S V F A N M L V T N F W M S T A N M Y T G M G G M V Q T V Q T R Y T F G A A L F V G W V A G G L T L I G G V M M C I A C R G L A P E E T N Y K A V S Y H A S G H S V A Y K P G G F K A S T G F G S N T K N K K I Y D G G A R T E D E V Q S Y P S K H D Y V

Target data

Function

Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling (By similarity). Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier (By similarity). Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription (By similarity). Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency (By similarity). Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways (By similarity). Isoform A1. Involved in the maintenance of homeostasis of the alveolar microenvironment via regulation of pH and subsequent T-cell activation in the alveolar space, is therefore indirectly involved in limiting C. neoformans infection. Isoform A2. Required for the formation of the gastric paracellular barrier via its role in tight junction formation, thereby involved in the response to gastric acidification.

Alternative names

Recommended products

Recombinant Human Claudin 18.2 (Active) protein is a Human Full Length protein, in the 1 to 261 aa range, expressed in HEK 293, with >95% purity and < 1 EU/µg endotoxin level.

Key facts

Purity
>95% HPLC
Endotoxin level
< 1 EU/µg
Expression system
HEK 293 cells
Biological activity
Immobilized Human Claudin 18.2 VLP at 5ug/ml (100ul/Well). Dose response curve for Anti-Claudin 18.2 Antibody, hFc Tag with the EC50 of 9.8ng/ml determined by ELISA.
Accession
P56856-2
Animal free
No
Carrier free
Yes
Species
Human
Concentration
Loading...
Storage buffer

Constituents: 99.99% PBS

Sequence info

Amino acid sequence

M A V T A C Q G L G F V V S L I G I A G I I A A T C M D Q W S T Q D L Y N N P V T A V F N Y Q G L W R S C V R E S S G F T E C R G Y F T L L G L P A M L Q A V R A L M I V G I V L G A I G L L V S I F A L K C I R I G S M E D S A K A N M T L T S G I M F I V S G L C A I A G V S V F A N M L V T N F W M S T A N M Y T G M G G M V Q T V Q T R Y T F G A A L F V G W V A G G L T L I G G V M M C I A C R G L A P E E T N Y K A V S Y H A S G H S V A Y K P G G F K A S T G F G S N T K N K K I Y D G G A R T E D E V Q S Y P S K H D Y V
Accession
P56856
Protein length
Full Length
Predicted molecular weight
29 kDa
Amino acids
1 to 261
Nature
Recombinant

Specifications

Form
Liquid

General info

Function

Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling (By similarity). Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier (By similarity). Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription (By similarity). Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency (By similarity). Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways (By similarity).

Sequence similarities

Belongs to the claudin family.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-80°C
Appropriate long-term storage conditions
-80°C
Aliquoting information
Upon delivery aliquot
Storage information
Avoid freeze / thaw cycle

This product is an active protein and may elicit a biological response in vivo, handle with caution.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Claudin 18.2 also known as claudin 18 CLDN18 or claudin-18.2 is a tight junction protein with a molecular mass of approximately 27 kDa. It is primarily expressed in gastric epithelial cells and certain lung tissues. Claudin 18.2 is part of the claudin family which plays a critical role in forming tight junctions to regulate paracellular transport and maintain cellular polarity. This isoform specifically expressed in the stomach is encoded by the CLDN18 gene located on chromosome 3. Researchers often use techniques like Immunohistochemistry (IHC) referred to as claudin 18.2 IHC or cldn18 IHC to study its expression and localization.

Biological function summary

Claudin 18.2 functions within tight junction complexes creating a barrier and controlling the movement of ions and molecules between cells. It is vital for the integrity and function of epithelial cell barriers in the stomach. The protein interacts with other claudins and cytoplasmic proteins to form these tight junctions essential for maintaining tissue organization and permeability. Its unique expression pattern makes it a significant marker for gastric tissue and a potential target for therapeutics.

Pathways

Claudin 18.2 is involved in cellular pathways related to adhesion and barrier function. It plays a role in the tight junction pathway critical for epithelial barrier integrity. This pathway involves interactions with other claudin proteins and ZO-1 which is a cytoplasmic plaque protein that links claudins to the actin cytoskeleton reinforcing cellular structure. Another pathway where claudin 18.2 is important is the gastro-intestinal epithelium maintenance pathway which is fundamental for protecting gastric tissues.

Associated diseases and disorders

Claudin 18.2 is a notable target in cancers especially gastric cancer. Its specific expression in gastric tissues makes it an attractive target for cancer immunotherapy as aberrant expression could indicate gastric cancer onset. Another disorder related to claudin 18.2 is asthma particularly where lung epithelial cells express this protein. Studies have identified links between claudin 18.2 and increased permeability in lung tissues implicating it in asthmatic pathophysiology. Its association with these conditions highlights the potential for claudin 18.2 as a diagnostic or therapeutic target in oncology and respiratory diseases.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

0 product images

    Downloads

    Product protocols

    For this product, it's our understanding that no specific protocols are required. You can:

    Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

    For licensing inquiries, please contact partnerships@abcam.com